Base de dados : MEDLINE
Pesquisa : D27.505.696.875.360.276.210.277 [Categoria DeCS]
Referências encontradas : 5016 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 502 ir para página                         

  1 / 5016 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27774589
[Au] Autor:Calhoun AH
[Ad] Endereço:Carolina Headache Institute, Durham, NC, USA.
[Ti] Título:Hormonal Contraceptives and Migraine With Aura-Is There Still a Risk?
[So] Source:Headache;57(2):184-193, 2017 Feb.
[Is] ISSN:1526-4610
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Unnecessary confusion still surrounds the use of combined hormonal contraceptives (CHCs) in the setting of migraine with aura (MwA). Clearing this confusion is a key issue for headache specialists, since most women with migraine have menstrual-related migraine (MRM), and some CHCs can prevent this particularly severe migraine. Their use, however, is still restricted by current guidelines due to concerns of increased stroke risk - concerns that originated over half a century ago in the era of high dose contraceptives. Yet studies consistently show that stroke risk is not increased with today's very low dose CHCs containing 20-25 µg ethinyl estradiol (EE), and continuous ultra low-dose formulations (10-15 µg EE) may even reduce aura frequency, thereby potentially decreasing stroke risk. This article clarifies the stroke risk of CHCs and examines their impact on migraine. It also examines how stroke risk is altered by the estrogen content of the CHC, by contributing factors such as smoking, age and hypertension, and by aura frequency. And finally, it puts these risks into a meaningful context with a risk/benefit assessment.
[Mh] Termos MeSH primário: Anticoncepcionais Orais Hormonais/efeitos adversos
Enxaqueca com Aura/epidemiologia
Acidente Vascular Cerebral/epidemiologia
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Contraceptives, Oral, Hormonal)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:180111
[Lr] Data última revisão:
180111
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE
[do] DOI:10.1111/head.12960


  2 / 5016 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29211679
[Au] Autor:Mørch LS; Skovlund CW; Hannaford PC; Iversen L; Fielding S; Lidegaard Ø
[Ad] Endereço:From Rigshospitalet, the Juliane Marie Center, Department of Gynecology, University of Copenhagen, Copenhagen (L.S.M., C.W.S., Ø.L.); and Academic Primary Care (P.C.H., L.I.) and Medical Statistics (S.F.), Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom.
[Ti] Título:Contemporary Hormonal Contraception and the Risk of Breast Cancer.
[So] Source:N Engl J Med;377(23):2228-2239, 2017 12 07.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Little is known about whether contemporary hormonal contraception is associated with an increased risk of breast cancer. METHODS: We assessed associations between the use of hormonal contraception and the risk of invasive breast cancer in a nationwide prospective cohort study involving all women in Denmark between 15 and 49 years of age who had not had cancer or venous thromboembolism and who had not received treatment for infertility. Nationwide registries provided individually updated information about the use of hormonal contraception, breast-cancer diagnoses, and potential confounders. RESULTS: Among 1.8 million women who were followed on average for 10.9 years (a total of 19.6 million person-years), 11,517 cases of breast cancer occurred. As compared with women who had never used hormonal contraception, the relative risk of breast cancer among all current and recent users of hormonal contraception was 1.20 (95% confidence interval [CI], 1.14 to 1.26). This risk increased from 1.09 (95% CI, 0.96 to 1.23) with less than 1 year of use to 1.38 (95% CI, 1.26 to 1.51) with more than 10 years of use (P=0.002). After discontinuation of hormonal contraception, the risk of breast cancer was still higher among the women who had used hormonal contraceptives for 5 years or more than among women who had not used hormonal contraceptives. Risk estimates associated with current or recent use of various oral combination (estrogen-progestin) contraceptives varied between 1.0 and 1.6. Women who currently or recently used the progestin-only intrauterine system also had a higher risk of breast cancer than women who had never used hormonal contraceptives (relative risk, 1.21; 95% CI, 1.11 to 1.33). The overall absolute increase in breast cancers diagnosed among current and recent users of any hormonal contraceptive was 13 (95% CI, 10 to 16) per 100,000 person-years, or approximately 1 extra breast cancer for every 7690 women using hormonal contraception for 1 year. CONCLUSIONS: The risk of breast cancer was higher among women who currently or recently used contemporary hormonal contraceptives than among women who had never used hormonal contraceptives, and this risk increased with longer durations of use; however, absolute increases in risk were small. (Funded by the Novo Nordisk Foundation.).
[Mh] Termos MeSH primário: Neoplasias da Mama/induzido quimicamente
Anticoncepcionais Orais Hormonais/efeitos adversos
Dispositivos Intrauterinos Medicados/efeitos adversos
[Mh] Termos MeSH secundário: Adolescente
Adulto
Distribuição por Idade
Neoplasias da Mama/epidemiologia
Dinamarca/epidemiologia
Estradiol/efeitos adversos
Estrogênios/efeitos adversos
Feminino
Seres Humanos
Progestinas/efeitos adversos
Estudos Prospectivos
Sistema de Registros
Risco
Medição de Risco
Fatores de Tempo
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Contraceptives, Oral, Hormonal); 0 (Estrogens); 0 (Progestins); 4TI98Z838E (Estradiol)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171215
[Lr] Data última revisão:
171215
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171207
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMoa1700732


  3 / 5016 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28957399
[Au] Autor:Yeh TN; Lin MC
[Ad] Endereço:Clinical Research Center, School of Optometry, University of California Berkeley, Berkeley, CA, United States of America.
[Ti] Título:Risk factors for severe Meibomian gland atrophy in a young adult population: A cross-sectional study.
[So] Source:PLoS One;12(9):e0185603, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Assess potential risk factors for severe Meibomian gland atrophy (SMGA) in a young adult population. METHODS: Cross-sectional study using medical history and ocular surface examination to evaluate relationships with study outcomes: SMGA, tear lipid layer (TLL) thickness, non-invasive (NITBUT) and fluorescein (FTBUT) tear breakup times, and symptoms using the Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire. RESULTS: One hundred one participants (101; 202 eyes; Age: mean±SD = 22.3±4.0 years) completed the study. Hormonal birth control (HBC) use was the only significant risk factor for SMGA (p = 0.028). Female HBC users had 4.8 times greater odds of having SMGA compared to female HBC non-users (p = 0.028), but the odds of having SMGA was similar between female HBC non-users and males (p = 0.885). Multivariable analysis suggested that the relationship between SMGA and TLL thickness was dependent on HBC use. Compared to female HBC non-users without SMGA, TLL thickness for HBC users was estimated to be 10 nm thinner if SMGA was absent (p = 0.007) and 21 nm thinner if SMGA was present (p<0.001). SMGA status had no significant impact on TLL thickness among female HBC non-users (p = 0.552). The effect of TLL thickness on FTBUT was small but significant (p = 0.026). TLL thickness was not significantly associated with NITBUT (p = 0.349). Neither FTBUT nor NITBUT was significantly associated with the SPEED score. CONCLUSION: HBC use may be associated with SMGA, supporting the hypothesis that SMGA could lead to thinner TLL. However, less evidence was present to support that thin TLL could lead to clinically detectable tear film instability and subsequently to increased ocular dryness symptoms. Further investigation with a larger sample size is warranted to confirm these findings.
[Mh] Termos MeSH primário: Glândulas Tarsais/patologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Anticoncepcionais Orais Hormonais/efeitos adversos
Estudos Transversais
Síndromes do Olho Seco/patologia
Feminino
Seres Humanos
Lipídeos/secreção
Masculino
Glândulas Tarsais/secreção
Índice de Gravidade de Doença
Inquéritos e Questionários
Lágrimas
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Contraceptives, Oral, Hormonal); 0 (Lipids)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170929
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0185603


  4 / 5016 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28934178
[Au] Autor:Tepper NK; Krashin JW; Curtis KM; Cox S; Whiteman MK
[Ad] Endereço:Div of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, CDC.
[Ti] Título:Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2016: Revised Recommendations for the Use of Hormonal Contraception Among Women at High Risk for HIV Infection.
[So] Source:MMWR Morb Mortal Wkly Rep;66(37):990-994, 2017 Sep 22.
[Is] ISSN:1545-861X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:CDC's U.S. Medical Eligibility Criteria for Contraceptive Use (U.S. MEC) (first published in 2010 and updated in 2016) provides evidence-based guidance for the safe use of contraceptive methods among U.S. women with certain characteristics or medical conditions (1), and is adapted from global guidance from the World Health Organization (WHO) and kept up to date based on continual review of published literature (2).* CDC recently evaluated the evidence and the updated WHO guidance on the risk for human immunodeficiency virus (HIV) acquisition among women using hormonal contraception. After careful review, CDC adopted the updated WHO guidance for inclusion in the U.S. MEC guidance; this guidance states that the advantages of progestin-only injectable contraceptive use (including depot medroxyprogesterone acetate [DMPA]) by women at high risk for HIV infection outweigh the theoretical or proven risks (U.S. MEC category 2). The guidance also includes an accompanying updated clarification, which states that "there continues to be evidence of a possible increased risk of acquiring HIV among progestin-only injectable users. Uncertainty exists about whether this is due to methodological issues with the evidence or a real biological effect. In many settings, unintended pregnancies and/or pregnancy-related morbidity and mortality are common, and progestin-only injectables are among the few types of methods widely available. Women should not be denied the use of progestin-only injectables because of concerns about the possible increased risk. Women considering progestin-only injectables should be advised about these concerns, about the uncertainty over whether there is a causal relationship, and about how to minimize their risk of acquiring HIV." Recommendations for other hormonal contraceptive methods (including combined hormonal methods, implants, and progestin-only pills) remain the same; there is no restriction for their use among women at high risk for HIV infection (U.S. MEC category 1).
[Mh] Termos MeSH primário: Anticoncepcionais Orais Hormonais/uso terapêutico
Definição da Elegibilidade
[Mh] Termos MeSH secundário: Centers for Disease Control and Prevention (U.S.)
Anticoncepcionais Orais Hormonais/efeitos adversos
Feminino
Infecções por HIV/epidemiologia
Seres Humanos
Gravidez
Gravidez não Planejada
Risco
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; PRACTICE GUIDELINE
[Nm] Nome de substância:
0 (Contraceptives, Oral, Hormonal)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170926
[Lr] Data última revisão:
170926
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170922
[St] Status:MEDLINE
[do] DOI:10.15585/mmwr.mm6637a6


  5 / 5016 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Maestá, Izildinha
Texto completo
[PMID]:28927899
[Au] Autor:Dantas PRS; Maestá I; Filho JR; Junior JA; Elias KM; Howoritz N; Braga A; Berkowitz RS
[Ad] Endereço:Department of Gynecology and Obstetrics, Botucatu Medical School, Postgraduate Program of Gynecology, Obstetrics and Mastology of São Paulo State University. Rubião Júnior District, Botucatu, São Paulo, Brazil; Rio de Janeiro Trophoblastic Disease Center, Brazilian Association of Gestational Trophob
[Ti] Título:Does hormonal contraception during molar pregnancy follow-up influence the risk and clinical aggressiveness of gestational trophoblastic neoplasia after controlling for risk factors?
[So] Source:Gynecol Oncol;147(2):364-370, 2017 Nov.
[Is] ISSN:1095-6859
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To evaluate the influence of hormonal contraception (HC) on the development and clinical aggressiveness of gestational trophoblastic neoplasia (GTN) and the time for normalization of human chorionic gonadotropin (hCG) levels. METHODS: A retrospective cohort study was conducted with women diagnosed with molar pregnancy, followed at the Rio de Janeiro Trophoblastic Disease Center, between January 2005 and January 2015. The occurrence of postmolar GTN and the time for hCG normalization between users of HC or barrier methods (BM) during the postmolar follow-up or GTN treatment were evaluated. RESULTS: Among 2828 patients included in this study, 2680 (95%) used HC and 148 (5%) used BM. The use of HC did not significantly influence the occurrence of GTN (ORa: 0.66, 95% CI: 0.24-1.12, p=0.060), despite different formulations: progesterone-only (ORa: 0.54, 95% CI: 0.29-1.01, p=0.060) or combined oral contraception (COC) (ORa: 0.50, 95% CI: 0.27-1.01, p=0.60) or with different dosages of ethinyl estradiol: 15mcg (ORa, 1.33, 95% CI 0.79-2.24, p=0.288), 20mcg (ORa: 1.02, 95% CI: 0.64-1.65, p=0.901), 30mcg (ORa: 1.17, 95% CI: 0.78-1.75, p=0.437) or 35mcg (ORa: 0.77, 95% CI: 0.42-1.39, p=0.386). Time to hCG normalization ≥10weeks (ORa: 0.58, 95% CI: 0.43-1.08, p=0.071) or time to remission with chemotherapy≥14weeks (ORa: 0.60, 95% CI: 0.43-1.09, p=0.067) did not significantly differ among HC users when compared to patients using BM, when controlling for other risk factors using multivariate logistic regression. CONCLUSIONS: The use of HC during postmolar follow-up or GTN treatment does not seem to increase the risk of GTN or its severity and does not postpone the normalization of hCG levels.
[Mh] Termos MeSH primário: Anticoncepcionais Orais Hormonais/administração & dosagem
Doença Trofoblástica Gestacional/epidemiologia
Mola Hidatiforme/terapia
[Mh] Termos MeSH secundário: Adulto
Gonadotropina Coriônica/sangue
Estudos de Coortes
Dispositivos Anticoncepcionais Femininos
Anticoncepcionais Orais Hormonais/efeitos adversos
Feminino
Seguimentos
Doença Trofoblástica Gestacional/sangue
Doença Trofoblástica Gestacional/etiologia
Doença Trofoblástica Gestacional/patologia
Seres Humanos
Mola Hidatiforme/sangue
Mola Hidatiforme/cirurgia
Gravidez
Estudos Retrospectivos
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Chorionic Gonadotropin); 0 (Contraceptives, Oral, Hormonal)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171108
[Lr] Data última revisão:
171108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170921
[St] Status:MEDLINE


  6 / 5016 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28918829
[Au] Autor:Monsuez JJ; Pham T; Karam N; Amar L; Chicheportiche-Ayache C; Menasché P; Desnos M; Dardel P; Weill I
[Ad] Endereço:APHP Hôpital R Muret, Hôpitaux Universitaires de Paris Seine-Saint-Denis, Paris, France. Electronic address: jean-jacques.monsuez@aphp.fr.
[Ti] Título:Awareness of Individual Cardiovascular Risk Factors and Self-Perception of Cardiovascular Risk in Women.
[So] Source:Am J Med Sci;354(3):240-245, 2017 Sep.
[Is] ISSN:1538-2990
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Cardiovascular risk factors (CVRFs) self-perception by women may be inaccurate. MATERIALS AND METHODS: A questionnaire was completed anonymously Online by women who self-reported their personal CVRF levels including age, weight, contraceptive use, menopausal status, smoking, diet and physical activities. Self-perceived risk was matched to actual cardiovascular risk according to the Framingham score. RESULTS: Among 5,240 young and middle-aged women with a high educational level, knowledge of personal CVRFs increased with age, from 51-90% for blood pressure (BP), 22-45% for blood glucose and 15-47% for blood cholesterol levels, between 30 and 65 years, respectively. This knowledge was lower for smoking compared with nonsmoking women: 62.5% vs. 74.5% for BP (P < 0.001), 22.7% vs. 33.8% for blood glucose (P < 0.001), 21.9% vs. 32.0% for cholesterol levels (P < 0.001). Knowledge of BP level was reduced among women using an estrogen-progestogen contraception (56.8% vs. 62.1%, P = 0.0031) and even more reduced among smokers (52.2%, P < 0.001). Conversely, women with leisure-time physical or sportive activity (60.5%), were less overweight or obese (22.4% vs. 34.2%, P < 0.001). They reported better knowledge of BP (72.4% vs. 68.3%, P < 0.001), blood cholesterol (31.1% vs. 26.4%, P < 0.001) and glucose levels (32.7% vs. 27.8%, P < 0.001). Self-perceived cardiovascular risk was rated low by 1,279 (20.4%), moderate by 3,710 (63.3%) and high by 893 (16.3%) women. Among 3,386 women tested using the Framingham score, 40.8% were at low, 25.2% at moderate and 33.8% at high risk. CONCLUSIONS: Knowledge of CVRFs and self-perception of individual risk are inaccurate in women. Educational interventions should be emphasized.
[Mh] Termos MeSH primário: Doenças Cardiovasculares
Conhecimentos, Atitudes e Prática em Saúde
Educação de Pacientes como Assunto
Autoimagem
[Mh] Termos MeSH secundário: Biomarcadores/sangue
Doenças Cardiovasculares/etiologia
Doenças Cardiovasculares/prevenção & controle
Anticoncepcionais Orais Hormonais/efeitos adversos
Exercício
Feminino
Seres Humanos
Obesidade/complicações
Fatores de Risco
Fumar/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Contraceptives, Oral, Hormonal)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170925
[Lr] Data última revisão:
170925
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170919
[St] Status:MEDLINE


  7 / 5016 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28875865
[Au] Autor:Callegari ET; Garland SM; Gorelik A; Reavley NJ; Wark JD
[Ad] Endereço:1Department of Medicine,Royal Melbourne Hospital,The University of Melbourne,Parkville,VIC 3050,Australia.
[Ti] Título:Predictors and correlates of serum 25-hydroxyvitamin D concentrations in young women: results from the Safe-D study.
[So] Source:Br J Nutr;118(4):263-272, 2017 Aug.
[Is] ISSN:1475-2662
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Vitamin D deficiency is a global public health concern. Studies of serum 25-hydroxyvitamin D (25(OH)D) determinants in young women are limited and few include objective covariates. Our aims were to define the prevalence of vitamin D deficiency and examine serum 25(OH)D correlates in an exploratory study of women aged 16-25 years. We studied 348 healthy females living in Victoria, Australia, recruited through Facebook. Data collected included serum 25(OH)D assayed by liquid chromatography-tandem MS, relevant serum biochemistry, soft tissue composition by dual-energy X-ray absorptiometry, skin melanin density, Fitzpatrick skin type, sun exposure using UV dosimeters and lifestyle factors. Mean serum 25(OH)D was 68 (sd 27) nmol/l and 26 % were vitamin D deficient (25(OH)D 2 h in the sun in summer daily, holidaying in the most recent summer period, serum Fe levels, height and multivitamin use were positively associated with 25(OH)D. Fat mass and a blood draw in any season except summer was inversely associated with 25(OH)D. Vitamin D deficiency is common in young women. Factors such as hormonal contraception, sun exposure and sun-related attitudes, as well as dietary supplement use are essential to consider when assessing vitamin D status. Further investigation into methods to safely optimise vitamin D status and to improve understanding of the impact of vitamin D status on long-term health outcomes is required.
[Mh] Termos MeSH primário: Deficiência de Vitamina D/etiologia
Vitamina D/análogos & derivados
[Mh] Termos MeSH secundário: Tecido Adiposo
Adolescente
Adulto
Estatura
Anticoncepcionais Orais Hormonais
Suplementos Nutricionais
Feminino
Seres Humanos
Ferro/sangue
Estilo de Vida
Prevalência
Estações do Ano
Luz Solar
Vitória/epidemiologia
Vitamina D/sangue
Deficiência de Vitamina D/sangue
Deficiência de Vitamina D/epidemiologia
Vitaminas/administração & dosagem
Vitaminas/sangue
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Contraceptives, Oral, Hormonal); 0 (Vitamins); 1406-16-2 (Vitamin D); 64719-49-9 (25-hydroxyvitamin D); E1UOL152H7 (Iron)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170919
[Lr] Data última revisão:
170919
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170907
[St] Status:MEDLINE
[do] DOI:10.1017/S0007114517002021


  8 / 5016 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28835399
[Au] Autor:Rooney JPK; Visser AE; D'Ovidio F; Vermeulen R; Beghi E; Chio A; Veldink JH; Logroscino G; van den Berg LH; Hardiman O; Euro-MOTOR Consortium
[Ad] Endereço:From the Academic Unit of Neurology (J.P.K.R., O.H.), Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland; Department of Neurology and Neurosurgery (A.E.V., J.H.V., L.H.v.d.B.), Brain Center Rudolf Magnus, University Medical Center Utrecht, the Netherlands; Department of Neuroscie
[Ti] Título:A case-control study of hormonal exposures as etiologic factors for ALS in women: Euro-MOTOR.
[So] Source:Neurology;89(12):1283-1290, 2017 Sep 19.
[Is] ISSN:1526-632X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To investigate the role of hormonal risk factors for amyotrophic lateral sclerosis (ALS) among women from 3 European countries. METHODS: ALS cases and matched controls were recruited over 4 years in Ireland, Italy, and the Netherlands. Hormonal exposures, including reproductive history, breastfeeding, contraceptive use, hormonal replacement therapy, and gynecologic surgical history, were recorded with a validated questionnaire. Logistic regression models adjusted for age, education, study site, smoking, alcohol, and physical activity were used to determine the association between female hormones and ALS risk. RESULTS: We included 653 patients and 1,217 controls. Oral contraceptive use was higher among controls (odds ratio [OR] 0.65, 95% confidence interval [CI] 0.51-0.84), and a dose-response effect was apparent. Hormone replacement therapy (HRT) was associated with a reduced risk of ALS only in the Netherlands (OR = 0.57, 95% CI 0.37-0.85). These findings were robust to sensitivity analysis, but there was some heterogeneity across study sites. CONCLUSIONS: This large case-control study across 3 different countries has demonstrated an association between exogenous estrogens and progestogens and reduced odds of ALS in women. These results are at variance with previous findings, which may be partly explained by differential regulatory, social, and cultural attitudes toward pregnancy, birth control, and HRT across the countries included. Our results indicate that hormonal factors may be important etiologic factors in ALS; however, a full understanding requires further investigation.
[Mh] Termos MeSH primário: Esclerose Amiotrófica Lateral
Anticoncepcionais Orais Hormonais/farmacologia
Terapia de Reposição de Estrogênios
Estrogênios/farmacologia
Progestinas/farmacologia
[Mh] Termos MeSH secundário: Idoso
Esclerose Amiotrófica Lateral/etiologia
Esclerose Amiotrófica Lateral/metabolismo
Esclerose Amiotrófica Lateral/prevenção & controle
Estudos de Casos e Controles
Relação Dose-Resposta a Droga
Feminino
Seres Humanos
Irlanda
Itália
Meia-Idade
Países Baixos
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Contraceptives, Oral, Hormonal); 0 (Estrogens); 0 (Progestins)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171004
[Lr] Data última revisão:
171004
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170825
[St] Status:MEDLINE
[do] DOI:10.1212/WNL.0000000000004390


  9 / 5016 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28829842
[Au] Autor:Pavela Banai I
[Ad] Endereço:Department of Psychology, University of Zadar, Zadar, Croatia.
[Ti] Título:Voice in different phases of menstrual cycle among naturally cycling women and users of hormonal contraceptives.
[So] Source:PLoS One;12(8):e0183462, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Previous studies have shown changes in women's behavior and physical appearance between the non-fertile and fertile phases of the menstrual cycle. It is assumed that these changes are regulated by fluctuations in sex hormone levels across the cycle. Receptors for sex hormones have been found on the vocal folds, suggesting a link between hormone levels and vocal fold function, which might cause changes in voice production. However, attempts to identify changes in voice production across the menstrual cycle have produced mixed results. Therefore, the purpose of this study was to investigate changes in sexually dimorphic vocal characteristics and quality of women's voices in different phases of the cycle and to compare these with users of monophasic hormonal contraception. Voice samples (vowel phonation) of 44 naturally cycling women were obtained in the menstrual, late follicular (confirmed by LH surge) and luteal phases, and in 20 hormonal contraceptive users across equivalent stages of the monthly cycle. Results showed that voices of naturally cycling women had higher minimum pitch in the late follicular phase compared with the other phases. In addition, voice intensity was at its lowest in the luteal phase. In contrast, there were no voice changes across the cycle in hormonal contraceptive users. Comparison between the two groups of women revealed that the naturally cycling group had higher minimum pitch in the fertile phase and higher harmonics to noise ratio in the menstrual phase. In general, present results support the assumption that sex hormones might have an effect on voice function. These results, coupled with mixed findings in previous studies, suggest that vocal changes in relation to hormonal fluctuation are subtle, at least during vowel production. Future studies should explore voice changes in a defined social context and with more free-flowing speech.
[Mh] Termos MeSH primário: Anticoncepcionais Orais Hormonais/uso terapêutico
Ciclo Menstrual
Voz
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Contraceptives, Oral, Hormonal)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170823
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0183462


  10 / 5016 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28712325
[Au] Autor:Farris M; Bastianelli C; Rosato E; Brosens I; Benagiano G
[Ad] Endereço:a Department of Gynecology, Obstetrics and Urology , Sapienza, University of Rome , Rome , Italy.
[Ti] Título:Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. effects on hemostasis.
[So] Source:Expert Rev Clin Pharmacol;10(10):1129-1144, 2017 Oct.
[Is] ISSN:1751-2441
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: The pharmacodynamic effects of various combined oral estrogen-progestin combinations (COC) are examined for their components alone or in the various combined formulations. Special emphasis is given to products containing natural estrogens. Areas covered: Recent information on the effect of androgens, estrogens, progestins, as well as various COC combinations on the coagulation cascade will be reviewed aiming at providing an updated picture. The present article reviews hemostatic changes occurring during use of classic and modern combinations of estrogens (ethinyl estradiol, estradiol, estradiol valerate and estetrol) and new progestins (desogestrel, gestodene, dienogest, drospirenone, nomegestrol acetate), compared to classic compounds, such as levonorgestrel. Both pro- and anti-coagulatory effects of COC in healthy women are detailed and possible links with incidence of thromboembolic events are discussed. Expert commentary: Overall, the picture is reassuring: the use of natural estrogens and of new generation progestins has reduced pro-coagulatory changes in healthy subjects, although the observed differences in the risk of venous thromboembolism between second and third generation progestins is still incompletely understood. At the same time, there still is a need for large comparative and surveillance studies before firm conclusions can be drawn. At any rate, available evidence indicates that hemostatic effects of the newer COC, especially those utilizing natural estrogens, are minimal and often remain with the normal range.
[Mh] Termos MeSH primário: Anticoncepcionais Orais Combinados/efeitos adversos
Anticoncepcionais Orais Hormonais/efeitos adversos
Hemostasia/efeitos dos fármacos
[Mh] Termos MeSH secundário: Androgênios/administração & dosagem
Androgênios/efeitos adversos
Anticoncepcionais Orais Combinados/administração & dosagem
Anticoncepcionais Orais Hormonais/administração & dosagem
Estrogênios/administração & dosagem
Estrogênios/efeitos adversos
Feminino
Seres Humanos
Progestinas/administração & dosagem
Progestinas/efeitos adversos
Tromboembolia Venosa/induzido quimicamente
Tromboembolia Venosa/epidemiologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Androgens); 0 (Contraceptives, Oral, Combined); 0 (Contraceptives, Oral, Hormonal); 0 (Estrogens); 0 (Progestins)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170718
[St] Status:MEDLINE
[do] DOI:10.1080/17512433.2017.1356718



página 1 de 502 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde